Published in J Virol on June 27, 2007
2-Benzene-sulfonamido-3-methyl-butyric acid. Acta Crystallogr Sect E Struct Rep Online (2012) 1.33
Current and Novel Inhibitors of HIV Protease. Viruses (2009) 1.10
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Curr Opin HIV AIDS (2008) 0.96
A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes. BMC Bioinformatics (2011) 0.89
Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process. Mol Biol Int (2012) 0.85
Synthesis and antidiabetic evaluation of benzenesulfonamide derivatives. Iran J Pharm Res (2013) 0.81
Quantitative comparison of errors in 15N transverse relaxation rates measured using various CPMG phasing schemes. J Biomol NMR (2012) 0.78
Investigating the hydrogen-bond acceptor site of the nicotinic pharmacophore model: a computational and experimental study using epibatidine-related molecular probes. J Comput Aided Mol Des (2013) 0.75
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem (1993) 4.80
ARP/wARP's model-building algorithms. I. The main chain. Acta Crystallogr D Biol Crystallogr (2002) 3.84
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science (1994) 3.44
The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses (1992) 2.69
Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure (2002) 2.69
How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J Mol Biol (2000) 2.62
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol (2004) 2.47
Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. J Biol Chem (1990) 1.95
Rigid protein motion as a model for crystallographic temperature factors. Proc Natl Acad Sci U S A (1991) 1.74
Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J Biol Chem (1993) 1.70
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci (2002) 1.49
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS (2000) 1.43
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J Virol (2003) 1.37
X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. Proc Natl Acad Sci U S A (1990) 1.34
Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem (1998) 1.29
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother (2000) 1.17
Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. J Med Chem (1997) 1.05
Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (2006) 1.05
Observation of a tetrahedral reaction intermediate in the HIV-1 protease-substrate complex. Biochem J (2005) 1.04
Peptidomimetic inhibitors of HIV protease. Curr Top Med Chem (2004) 0.99
Lysine sulfonamides as novel HIV-protease inhibitors: optimization of the Nepsilon-acyl-phenyl spacer. Bioorg Med Chem Lett (2003) 0.84
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol (2003) 2.98
Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure (2002) 2.69
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem (2005) 2.58
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol (2004) 2.47
Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol (2004) 2.39
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS (2009) 2.15
Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol (2002) 1.71
Covariation of amino acid positions in HIV-1 protease. Virology (2003) 1.65
Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol (2004) 1.65
Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure (2010) 1.65
Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A (2010) 1.65
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci (2002) 1.49
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc (2008) 1.43
The challenge of developing robust drugs to overcome resistance. Drug Discov Today (2011) 1.43
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol (2010) 1.39
Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J Biol Chem (2012) 1.38
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J Virol (2003) 1.37
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog (2012) 1.30
First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol (2012) 1.28
PTEN enters the nucleus by diffusion. J Cell Biochem (2005) 1.28
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev (2008) 1.26
Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology (2006) 1.22
Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure (2007) 1.20
Molecular Basis for Drug Resistance in HIV-1 Protease. Viruses (2010) 1.20
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One (2012) 1.19
Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. Nat Struct Mol Biol (2008) 1.17
Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. J Med Chem (2006) 1.17
Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J Virol (2006) 1.15
Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. J Mol Biol (2011) 1.14
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS (2009) 1.13
Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure (2013) 1.13
Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations. Proteins (2003) 1.12
Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle (2010) 1.12
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des (2007) 1.12
Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. J Virol (2006) 1.10
Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J Med Chem (2005) 1.10
Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol (2009) 1.07
Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (2006) 1.05
Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease. J Virol (2011) 1.05
Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins (2007) 1.04
Decomposing the energetic impact of drug resistant mutations in HIV-1 protease on binding DRV. J Chem Theory Comput (2010) 1.02
Point mutants of EHEC intimin that diminish Tir recognition and actin pedestal formation highlight a putative Tir binding pocket. Mol Microbiol (2002) 1.01
Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro. J Virol (2013) 1.01
Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase. J Med Chem (2005) 1.01
Contribution of Ser386 and Ser396 to activation of interferon regulatory factor 3. J Mol Biol (2008) 1.00
The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways. J Virol (2010) 0.99
Hydrophobic core flexibility modulates enzyme activity in HIV-1 protease. J Am Chem Soc (2012) 0.99
Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease. Proteins (2008) 0.99
Differential Flap Dynamics in Wild-type and a Drug Resistant Variant of HIV-1 Protease Revealed by Molecular Dynamics and NMR Relaxation. J Chem Theory Comput (2012) 0.98
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem (2007) 0.97
Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease. ACS Chem Biol (2012) 0.96
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Curr Opin HIV AIDS (2008) 0.96
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS (2009) 0.96
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology (2012) 0.96
Additivity in the analysis and design of HIV protease inhibitors. J Med Chem (2009) 0.95
Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease. J Biol Chem (2012) 0.94
Nitric oxide-mediated inhibition of Hdm2-p53 binding. Biochemistry (2002) 0.94
Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. J Med Chem (2010) 0.93
Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. Eur J Med Chem (2006) 0.90
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther (2011) 0.90
The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities. Protein Sci (2013) 0.88
Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development. PLoS One (2011) 0.88
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res Hum Retroviruses (2006) 0.88
Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrob Agents Chemother (2004) 0.87
Competition between Ski and CREB-binding protein for binding to Smad proteins in transforming growth factor-beta signaling. J Biol Chem (2007) 0.87
Structural analysis of human immunodeficiency virus type 1 CRF01_AE protease in complex with the substrate p1-p6. J Virol (2008) 0.86
Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. Antiviral Res (2009) 0.86
Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease. J Am Chem Soc (2014) 0.85
Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease. Biophys J (2010) 0.85
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chem Biol (2013) 0.84
Structure-based prediction of potential binding and nonbinding peptides to HIV-1 protease. Biophys J (2003) 0.83
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data. AIDS Res Hum Retroviruses (2010) 0.83
Toward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis. Chem Biol Drug Des (2009) 0.82
Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol (2013) 0.82
Structural insights into neuronal K+ channel-calmodulin complexes. Proc Natl Acad Sci U S A (2012) 0.82
Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease. Protein Sci (2012) 0.82
Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. ACS Chem Biol (2012) 0.82
Efficient Computation of Small-Molecule Configurational Binding Entropy and Free Energy Changes by Ensemble Enumeration. J Chem Theory Comput (2013) 0.82
Testing the substrate-envelope hypothesis with designed pairs of compounds. ACS Chem Biol (2013) 0.81
Conformational analysis of TMC114, a novel HIV-1 protease inhibitor. J Chem Inf Model (2008) 0.81
Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem Biol (2014) 0.81
A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies. Arch Biochem Biophys (2012) 0.80
Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50. J Virol (2013) 0.80
Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance. J Med Chem (2012) 0.79
RecA dimers serve as a functional unit for assembly of active nucleoprotein filaments. Biochemistry (2006) 0.79
Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2011) 0.79
TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrob Agents Chemother (2011) 0.79
Substrate specificity in HIV-1 protease by a biased sequence search method. Proteins (2006) 0.78
A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid. Biochemistry (2013) 0.78
Quantitative comparison of errors in 15N transverse relaxation rates measured using various CPMG phasing schemes. J Biomol NMR (2012) 0.78
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virol J (2014) 0.76
Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr (2014) 0.76
Discovery of 4'-azido-2'-deoxy-2'-C-methyl cytidine and prodrugs thereof: a potent inhibitor of Hepatitis C virus replication. Bioorg Med Chem Lett (2012) 0.76
Mass spectrometry tools for analysis of intermolecular interactions. Methods Mol Biol (2012) 0.75